Section Review—Cardiovascular & Renal: Recent Advances in Imidazoline Receptor Research

References

• BOUSQUET P, FELDMAN J, SCHWARTZ J: Central cardio-vascular effects of a-adrenergic drugs: Difference be-tween catecholamines and imidazolines. J. Pharm. Exp. Ther. (1984) 230:230-236. The first reference to imidazoline receptors.
   Google Scholar
• KOBINGER W: Central alpha-adrenergic systems as tar-gets for hypotensive drugs. Rev. Physiol. Bloc hem. (1978) 81:39–100.
   Google Scholar
• TIMMERMANS PBMW, VAN ZWIETEN PA: a2-adrenocep-stors: classification, loralbation, mechanisms and targetfor drugs. J. Med. Chem. (1982) 25:1389-1401. A thorough review of centrally-acting hypotensive drugs referring to the a-adrenergic theory.
   Google Scholar
• STARKE K, MONTEL H, GAYK W, MERKER R: Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery, a-sym-pathomimetic inhibition of neurogenic vasoconstric-tion. Naunyn Schmiedeberg's Arch. Pharmacol. (1974) 285:133–150.
   Google Scholar
• STARKE K: Alpha-adrenoceptors subclassification. Rev. Physiol. Biochem. Pharmacol. (1981) 88:199–236.
   PubMedGoogle Scholar
• RUFFOLO RR, RICE PJ, PATIL PN, HAMADA A, MIT "FR DD: Differences in the applicability of the Easson-Stedman hypothesis to the al and C52-adrenergic effects of phenylethylamines and imiriazolines. Eur.J. Pharmacol. (1983) 86:471-475. First report on pharmacological differences between imidazolines and catecholamines.
   Google Scholar
• KOBINGER W, PICHLER L: Evidence for direct alpha-ad-renoceptor stimulation of effector neurons in cardio-vascular centers by clonidine. Eur. J. Pharmacol. (1974) 27:151–154.
   PubMed Web of Science ®Google Scholar
• KOBINGER W, PICHLER L: The central modulatory effectof clonidine on the cardiodepressor reflex after sup-pression of synthesis and storage of noradrenaline. Eur. J. Pharmacol. (1975) 30:56-62. A report on the non-involvement of presynaptic a-adrenoceptors in the central cardiovascular effects of clonidine.
   Google Scholar
• DELBARRE B, scHmrrr H: Sedative effects of a-sym-pathomimetic drugs and their antagonism by adrener-gic and cholinergic blocking drugs. Eur. J. Pharmacol. (1971) 13:356–363.
   PubMed Web of Science ®Google Scholar
• SCHMITT H: The pharmacology of clonidine and related products. In: Handbook of Experimental Pharmacology. Vol. 39. Antihypertensive Agents. F Gross (Ed.). Springer, Berlin/Heidelberg/New York (1977):299–396.
   Google Scholar
• BOUSQUET P, GUERTZENSTEIN PG: Localization of the scentral cardiovascular action of clonidine. Br. J. Phar-macol. (1973) 49:573-579. First localisation of the site of the hypotensive action of clonidine in the ventrolateral part of the brainstem.
   Google Scholar
• BOUSQUET P, FELDMAN J, BLOCH R, SCHWARTZ J: The .nucleus reticularts lateralis: a region highly sensitive to clonidine. Eur. J. Pharmacol. (1981) 69:389-392. A report on the precise localisation of the trigger zone of clonidine within the brainstem.
   Google Scholar
• WOLF DL, MOHRLAND JS: Lateral reticular formation as a site for morphine and clonidine induced hyperten-sion. Eur. J. Pharmacol. (1984) 98:93–95.
   PubMed Web of Science ®Google Scholar
• VAN ZWIETEN PA: Interactions interfering with central adrenoreceptor activity and hypotension of centrally acting antihypertensive agents. In: Hypertension and Brain Mechanisms. de Jong W, Provoost AP, Shapiro A (Eds.). Elsevier, Amsterdam (1977):385–396.
   Google Scholar
• ZANDBERG P, DE JONG W: Alpha-methylnoradrenaline induced hypotension in the nucleus tractus solitarii of the rat. Neuropharrnacology (1977) 16:219–222.
   PubMed Web of Science ®Google Scholar
• HAEUSLER G: Clonidine-induced inhibition of sympa-thetic nerve activity: No indication for a central presy-naptic or an indirect sympathomimetic mode of action. Naunyn Schmiedeberg's Arch. Pharmacol. (1974) 286:97–111.
   Google Scholar
• HAEUSLER G, FINCH L: On the nature of the centralhypotensive effect of clonidine and a-methyldopa. I. Pharmacol. (Paris) (1972) 3:544–545.
   Google Scholar
• BOUSQUET P, FELDMAN J, SCHWARTZ J: The mednIlary cardiovascular effects of imidazolines and some GABA analogues: a review. J. Auton. Nerv. Syst. (1985) 14:263–270.
   PubMedGoogle Scholar
• WARNKE E, HOEFKE W: Influence of central pretreat-ment with 6-hydroxydopamine on the hypotensive effect of clonidine. Arzneim. Forsch. (1977) 27:2311–2313.
   PubMed Web of Science ®Google Scholar
• MEELEY MP, ERNSBERGER PR, GRANATA AR, REIS DJ: An .endogenous clonidine-displacing substance from bo- vine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci. (1986) 38:1119-1126. A report on the effects of brain extracts containing an imidazoline-like substance.
   Google Scholar
• ERNSBERGER PR, MEELEY MP, MANN JJ, REIS DJ: Clo-••nidine binds to imidazole binding sites as well as a2-adrenoceptors in the ventrolateral medulla. Eur. Pharmacol. (1987) 134:1-13. The first demonstration of the existence of imidazoline specific binding sites.
   Google Scholar
• COUPRY I, PODEVIN RA, DAUSSE JP, PARINI A: Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney. Biochem. Biophys. Res. Commun. (1987) 147:1055–1060.
   Google Scholar
• PARINI A, COUPRY I, GRAHAM RM, UZIELLI I, ATLAS D, LANIER SM: Characterization of an imidazoline/ guanidinium receptive site distinct from the ou-adren-ergic receptor. J. Biol. Chem. (1989) 264:11874-11878. A report on imidazoline receptors.
   Google Scholar
• LANGIN D, LAFONTAN M: [311]-idazoxan binding at non-az-adrenoceptors in rabbit adipocyte membranes. Eur. I Pharmacol.(1989) 159:199–203.
   PubMed Web of Science ®Google Scholar
• WIKBERG JES: High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nerv-ous system: description of a putative idazoxan-recep-tor. Pharmacology & Toxicology (1989) 64:152–155.
   PubMedGoogle Scholar
• BRICCA G, DONTENWILL M, MOLINES A, FELDMAN J, •BELCOURT A, BOUSQUET P: Evidence for the existenceof a homogenous population of imidazoline receptors in the human brain.stem. Eur. j Pharmacol. (1988) 150:401-402. The first report on human cerebral imidazoline binding sites.
   Google Scholar
• TIBIRICA E, MERMET C, FELDMAN J, GONON F, BOUSQUET P: Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evoked by clonidine: a voltanunet-ric approach. J. Pharm. Exp. Ther. (1989) 250:642-647. A functional study differentiating the mechanism of the hypotensive action from that of the sedation induced by clonidine.
   Google Scholar
• TIBIRICA E, FELDMAN J, MERMET C, MONASSIER L, GONON F, BOUSQUET P: Selectivity of rihnenidine for the nucleus reticularts lateralis, a ventrolateral medul-lary structure containing imidazoline-preferring recep-tors. Eur. J. Pharmacol. (1991) 209:213–221.
   PubMed Web of Science ®Google Scholar
• DE SARRO GB, ASCIOTI C, FROIO F, LIBRI V, NISTICO G:Evidence that locus coeruleus is the site where clo-nidine and drugs acting at al.- and a2-adrenoceptors affect sleep and arousal mechanisms. Br. J. Pharmacol. (1987) 90:675–685.
   Google Scholar
• SAVOLA JM, VIRTANEN R: Central a2-adrenoceptors arehighly stereoselective for dexmedetomidine the dextro enantiomer of medetomidine. Eur. J. Pharmacol. (1991) 195:193–199.
   PubMed Web of Science ®Google Scholar
• VAN HOUTTE PM, BARNARD EA, COSMIDES GJ, HUM-
   Google Scholar
• PHREY PPA, SPEDDING M, GODFRAIND T: InternationalUnion of Pharmacology committee on receptor nomen-clature and drug classification. Pharmacol. Rev. (1994) 46(2):111–116. The imidazoline receptors are officially included in the IUPHAR receptor list.
   Google Scholar
• BOUSQUET P, GRENEY H, BENNAI F, FELDMAN J, STUTZMANN J, BELCOURT A, DONTENWILL M: imida-zoline receptors and cardiovascular regulations: a state-ment. NY Acad. Sci. (1995). In press.
   Google Scholar
• MICHEL MC, INSEL PA: Are there multiple imidazolinebinding sites? Trends Pharmacol. Sci. (1989)10:342–344.
   Google Scholar
• MIRALLES A, OLMOS G, SASTRE M, BARTUREN F, MARTIN I, GARCIA-SEVILLA J: Discrimination and pharmacologi-cal characterization of 12 imidazolines sites with [3H]ida-zoxan and alpha-2 adrenoceptors with E3111111E 821002 (2-methoxy idazoxan) in the human and rat brains. J Pharm. Exp. Ther. (1992) 264:1187–1197.
   Web of Science ®Google Scholar
• CHAN SLF, BROWN CA, SCARPELLO la, MORGAN NG: The imidazoline site involved in control of insulin secre-tion: characteristics that distinguish it from Ii and 12 sites. Br. J. Pharmacol. (1994) 112:1065-1070. A report on pancreatic imidazoline receptors mediating imidazoline-induced effects on insulin secretion.
   Google Scholar
• GOTHERT M, MOLDERINGS GJ: Involvement of presy- naptic imid" azoline receptors in the az-adrenoceptor-in-dependent inhibition of noradrenaline release by imidazoline derivatives. Naunyn Schmiedeberg's Arch .Pharmacol. (1991) 343:271-282. The first report of the existence of imidazoline receptors at the presynaptic level.
   Google Scholar
• LACHAUD-PEI WI V, PODEVIN RA, CHRETIEN I, PARINIA: Imidazoline-guanidinium receptive sites in basolat-eral membranes from human kidney. Eur.J. Pharmacol. (1991) 206:23–31.
   PubMed Web of Science ®Google Scholar
• LANIER SM, IVKOVIC B, SINGH I, NEUMEYER JL, BAK-THAVACHALAM V: Visualization of multiple imida- Olt zoline/guanidinium receptive sites. J. Biol. Chem. ( 1993) 268:16047–16051.
   Google Scholar
• LIMON I, COUPRY I, LANIER SM, PARINI A: Purification and characterization of mhochondrial imidazoline-guanidinium receptive site from rabbit kidney. J. Biol. Chem. (1992) 267:21645-21649. The first demonstration of a mitochondria' localisation of some imidazoline binding sites: an attempt to purify these receptive sites.
   Google Scholar
• SASTRE M, GARCIA-SE VILLA JA: Opposite age-dependent changes of a2A-adrenoceptors and nonadrenoceptor [311]ki-gzoxan binding sites (I2-imidazoline sites) in the human brain: strong correlation of 12 with monoamine oxidase-B sites. j Neurochem. (1993) 61:881–889.
   PubMed Web of Science ®Google Scholar
• CARPENE C, COLLON P, REMAURY A, CORDI A, HUDSON A, NUTT D, LAFONTAN M: Inhibition of amine oxidase activity by derivatives recognizing I2-bni•i•voline sites. j Pharm. Exp. 7ber. (1995), In press.
   Google Scholar
• PILETZ JE, SLE1TEN K: Nonadrenergic imidazoline bind-ing sites on human platelets. J. Pharm. Exp. Then (1993) 267:1493–1502.
   PubMed Web of Science ®Google Scholar
• WANG H, REGUNATHAN S, MEELEY MP, REIS DJ: Isolation and characterization of imidazoline receptor proteinfrom bovine adrenal chromaffin cells. Mol. Pharmacol. (1992) 42:792-801. The first purification of a peripheral imidazoline binding protein.
   Google Scholar
• BENNAI F, GRENEY H, STUTZMANN J, BOUSQUET P, DONTENWILL M: Development of anti-idiotypic anti-bodies specific for the human cerebral imidazoline receptor. 1VY Acad. Sci. (1995). In press.
   Google Scholar
• GRENEY H, BENNAT F, MOLINES A, BELCOURT A, DON-TENWILL M, BOUSQUET P: Isolation of a human cerebral imidazoline-specific binding protein. Eur. J. Pharmacol. (1994) 265:R1-R2. The first purification of a human cerebral imidazoline binding protein.
   Google Scholar
• ESCRIBA PV, SASTRE M, WANG H, REGUNATHAN S, REISDJ, GARCIA-SEVILLA JA: Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci. Letters (1994) 178:81–84.
   PubMed Web of Science ®Google Scholar
• BRICCA G, GRENEY H, ZHANG J, DONTENWILL M, STUTZMANN J, BELCOURT A, BOUSQUET P: Human brain imidazoline receptors: Further characterization with [31I]clonidine. Eur. J. Pharmacol. - Molec. Pharmacol. Sect. (1994) 266:25-33. An extensive report on the imidazoline-specific binding properties of "3H1clonidine in the brain.
   Google Scholar
• REGUNATHAN S, REIS DJ: Distinct sub-cellular localiza-tion of a2-adrenergtc receptors in bovine cerebral cor-tex. Fund. Clin. Pharmacol. (1992) 6:53S.
   Google Scholar
• CHAN SLF, DUNNE MJ, STILLINGS MR, MORGAN NG: Thea2-adrenoceptor antagonist efaroxan modulates K+-ATP channels in insulin-secreting cells. Eur. J. Pharma-col. (1991) 204:41–48.
   PubMed Web of Science ®Google Scholar
• PLANT TD, HENQUIN JC: Phentolamine and yohimbine Inhibit ATP-sensitive K+-channels in mouse pancreatic 0-cells. Brit. J. Pharmacol. (1990) 101:115–120.
   PubMed Web of Science ®Google Scholar
• WIKBERG JES, UHLEN S: Further characterization of the guinea pig cerebral cortex idazoxan receptor, solubili-zation distinction from the imidazoline site, and dem-onstration of cirazoline as an idazoxan receptor selective drug. J. Neurochem. (1990) 55:192–203.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, REGAN JW, GERHARDT MA, NEUBIG RR, INSEL PA, MOTULSICY H: Non-adrenergic Pillidazoxan binding sites are physically distinct from a2-adrenocep-tors. Mot. Pharmacol. (1990) 37:65-68. An additional study that distinguishes imidazoline binding sites from a2-adrenoceptors.
   Google Scholar
• BRICCA G, GRENEY H, DONTENWILL-KIEFFER M, ZHANGJ, BELCOURT A, BOUSQUET P: Heterogeneity of the specific imidazoline binding of [3111idazoxan in the human cerebral cortex. J. Neurochem. Int. (1993) 2:153–163.
   Google Scholar
• YABLONSKY F, RIFFAUD JP, LACOLLE JY, DAUSSE JP: Evidence for non-adrenergic binding sites for [311]ida-zoxan in the smooth musde of rabbit urethra. Eur. j Pharmacol. (1988) 154:209–212.
   PubMed Web of Science ®Google Scholar
• REMAURY A, PARIS H: The insulin-secreting cell line, •RINm5F, expresses an alpha-2D adrenoceptor and non-adrenergic idazoxan-binding sites. J. Pharm. Exp. Ther. (1991) 260:417-426. The first report on a cell line expressing specific imidazoline binding sites.
   Google Scholar
• REGUNATHAN S, MEELEY MP, REIS DJ: Expression ofnon-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenaL Bio-chem. Pharmacol. (1993) 45:1667–1675.
   Web of Science ®Google Scholar
• ANGEL I, LE ROUZIC M, PIMOULE C, GRAHAM D, ARBILLAS: [311]-Cirazoline as a tool for the characterization of imidazoline sites. /VY Acad. Sc!. (1995). In press.
   Google Scholar
• NUT!' DJ, FRENCH N, HANDLEY S, HUDSON A, HUSBANDSS, JACKSON H, JORDAN S, LALIES MD, LEWIS J, LIONE L, MALLARD N, PRATT J: Functional studies of specific imidazoline-2 receptor ligands. IVY Acad. Sc!. (1995). In press.
   Google Scholar
• DE VOS H, BRICCA G, DE KEYSER J, DE BACKER JP,BOUSQUET P, VAUQUELIN G: Imidazoline receptors, non-adrenergic idazoxan binding sites and a2-adreno-ceptors in the human central nervous system. Neurosci-ence (1994) 59(3):589–598.
   PubMedGoogle Scholar
• IVKOVIC B, BAKTHAVACHALAM V, ZHANG W, PARINI A,DIZ D, BOSCH S, SINGH I, NEUMEYER JL, LANIER SM: Development of a high-affinity radioiodinated ligand for identification of imidazoline/guanidinhun recep-tive sites (IGRS): intratissue distribution of IGRS in liver, forebrain, and kidney. J. Pharm. Exp. Ther. (1994) 46: 15–23.
   Google Scholar
• GRENEY H, BRICCA G, DONTENWILL M, STUTZMANN J,BOUSQUET P, BELCOURT A: Characterization of imida-zoline binding protein(s) solubilized from human brainstem: studies with OHlidazoxan and PHI do-nidine. Neurochem. Int. (1994) 25:183–191.
   PubMedGoogle Scholar
• ATLAS D, BURSTEIN Y: Isolation of an endogenous do- nidine-displacing substance form rat brain. FESS Lett. (1984) 170:387-390. The first partial purification of brain extracts containing an imida-zoline-like substance.
   Google Scholar
• ATLAS D, BURSTEIN Y: Isolation and partial purificationof a clonidine displacing endogenous brain substance. Eur. J. Biochem. (1984) 144:287–293.
   PubMedGoogle Scholar
• ERNSBERGER PR, MEELEY MP, REIS DJ: An endogenoussubstance with clonidine like properties: selective bind-ing to imidazole sites in the ventrolateral medulla. Brain Res. (1988) 441:309–318.
   PubMed Web of Science ®Google Scholar
• BOUSQUET P, FELDMAN J, ATLAS D: An endogenous,non- catecholamine clonidine antagonist increases mean arterial blood pressure. Eur. J. Pharmacol. (1986) 124:167–170.
   PubMed Web of Science ®Google Scholar
• LI G, REGUNATHAN S, BARROW CJ, ESHRAGHI J, COOPERR, REIS DJ: Agmatine: an endogenous clonidine displac-ing substance in the brain. Science (1994) 263:966–969.
   PubMed Web of Science ®Google Scholar
• VERBEUREN TJ, DINH XUAN AT, KOENIG-BERARD E, VITOU P: Rilmenidine. Cardiovasc. Drug Rev. (1990) 8:56–70.
   Google Scholar
• CHRISP P, FAULDS D: Moxonidine, a review of its phar-macology, and therapeutic use in essential hyperten-sion. Drugs (1992) 44(6):993–1012.
   PubMed Web of Science ®Google Scholar
• FELDMAN J, TIBIRICA E, BRICCA G, DONTENWILL M, BELCOURT A, BOUSQUET P: Evidence for the involve-ment of imidazoline receptors in the central hypoten-sive effect of rihnenicline in the rabbit. Br. J. Pharmacol, (1990) 100:600-604. Rilmenidine was proposed as the first centrally acting hypotensive drug selective for the imidazoline receptors.
   Google Scholar
• HEAD GA, GODWIN SJ, SANNAJUST F: Differential recep-tors involved in the cardiovascular effects of clonidine and rilmenidine in conscious rabbits. J. Hypertens. (1993) 11\(Suppl. 5):S322–S325.
   Google Scholar
• BRICCA G, DONTENWILL M, MOLINES A, FELDMAN J,TI-BIRICA E, BELCOURT A, BOUSQUET P: Rilmenidine se-lectivity for imidazoline receptors in human brain. Eur. Pharmacol. (1989) 163:373–377.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER P, HAXHIU MA, GRAFF LM, COLLINS LA, DRESHAJ I, GROVE LD, GRAVES ME, SCHAFER GS, CHRIS-TEN MO: A novel mechanism of action for hypertension control: moxonidine as a selective Ii-imidlazoline agonist Cardiovasc. Drugs. Ther. (1994) 8:27–41.
   Google Scholar
• HAYASHI Y, KAMIBAYASHI T: The role of imidazoline receptors in halothane-epinephrine arrhythmtos. find International Symposium on Imidazoline receptors. New York (1994). Abstract No. S35.
   Google Scholar
• THOMAS GP, STEPHEN PM: Protective action of clonidineagainst the arrhythmogenic and lethal effects of ouabain in guinea-pigs. Br. J. Pharmacol. (1991) 104:995–999.
   PubMed Web of Science ®Google Scholar
• MACKAIGUE JP, HARRON DWG: The effects of ril-mertidine on tests of autonomic function in humans. Clin. Pharmacol. Ther. (1992) 52:511–517.
   PubMed Web of Science ®Google Scholar
• HARRON DWG: Antihypertensive drugs and baroreftex sensitivity: effect of rilmenldine. AmericanJ. Med. (1989) 87(Suppl. 3C):57S–62S.
   Google Scholar
• CALLENS-EL AMRANI F, PAOLAGGI F, SWYNGHEDAUW B: Remodelling of the heart in DOCA-salt hypertensive rats by propranolol and by an alphaz-agonist, ril-menidine. J. Hypertens. (1989) 7:947–954.
   PubMedGoogle Scholar
• MAYOROV D, CHERNOBELSKI M, MEDVEDEV 0: Sym-pathoinItibitory action of rilmenidine in conscious sinoaortically denervated rats. J. Cardiovasc. Pharmacol. (1993) 22:314–320.
   PubMed Web of Science ®Google Scholar
• 'CLINE RL, CECHETTO DF: Renal effects of riknenktine in anaesthetized rats: importance of renal nerves. J. Pharm. Exp. Ther. (1993) 266(3):1556–1562.
   Google Scholar
• GHAEMMAGHAMI F, IBANEZ J, GEELEN G, VINCENT M, FRUTOSO J: Effects of swim training alone and in combination with clonidine and rilmenidine on blood pressure, plasma electrolytes, vasopressin, and renin activity in spontaneously hypertensive rats. J Cardiovasc. Pharmacol. (1990) 5:68–74.
   Google Scholar
• SCHULZ A, HASSELBLATT A: An insulin-releasing prop-erty of ituidazoline derivatives is not muted to com-pounds that block a-adrenoceptors. Naunyn Schmiedeberg's Arch. Pharmacol. (1989) 340:321–327.
   Google Scholar
• SCHULZ A, HASSELBLATT A: Dual action of clonidine on Insulin release: suppression, but stimulation when a2-adrenoceptors are blocked. Naunyn Schmiedeberg's Arch . Pharmacol. (1989) 340:712–714.
   Google Scholar
• BERDEU D, GROSS R, RIBES G, LOUBATIERES-MARIANI MM, BER'FRAND G: Effects of imidazolines and deriva-tives on insulin secretion and vascular resistance in perfused rat pancreas. Eur.J. Pharmacol. (1994) 254:119–125.
   PubMed Web of Science ®Google Scholar
• FILLASTRE JP, LETAC B, GALINIER F, LEBIHAN G, SCHWARTZ j: A multicenter double-blind study of ril-menidine and clonidine in 333 hypertensive patients. American. J. CardioL (1988) 61:81D–85D.
   Google Scholar
• RUIZ J, MARTIN I, CALLADO LF, MAENA JJ, BARTUREN F, GARCIA-SEVILLA JA: Non-adrenoceptor [3H]idazoxan binding sites (I2-itnidazoline sites) are increased in postmortem brain from patients with Alzhehner's dis-ease. Neurosci . Letters (1993) 160:109–112,
   PubMed Web of Science ®Google Scholar
• MAENA JJ, BARTUREN F, MARTIN I, GARCIA-SEVILLA JA: Evidence of increased non-adrenoceptor PH] idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol. Psychiatry (1993) 34:498–501.
   PubMed Web of Science ®Google Scholar
• KRYSTAL JH, MCDOUGLE CHJ, WOODS SW, PRICE LH, HENNINGER GR, CHARNEY DS: Dose-response relation-ship for oral idazoxan effects in healthy human sub-jects: comparison with oral yohimbine. Psychopharmacology (1992) 108:313–319,
   PubMed Web of Science ®Google Scholar
• OSMAN OT, RISBY E, HSIAO J, P011ER WZ: Chronic idazoxan in humans pro duces altered responses to iv alprazolam. ACNP Annual Meeting. Puerto Rico (1988). Poster presentation.
   Google Scholar
• CHARNEY P, PRICE LH, HENNINGER GR: Idazoxan: a novel az-antagonist and antidepressant. Arch. Gen. Psy-chiatry (1988) 43:1155–1161.
   Google Scholar
• GLUE P, WILSON S, CAMPLING GM, KNIGHTLY M, FRANK-LIN M, COWEN PhJ, NUTT DJ: Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology (1992) 17(2/3):261–266.
   Google Scholar
• OSMAN OT, RUDORFER MV, POTTER WZ: Idazoxan a selective az-antagonist and effective sustained antide-pressant in two bipolar depressed patients. Arch. Gen. Psychiatry (1989) 46:958–959.
   PubMed Web of Science ®Google Scholar
• LITMAN RE, HONG WW, 'WEISSMAN EM, SU TP, P011ERWZ, PICKAR D: Idazoxan, an a2-antagonist, augments ftuphenazine in schizophrenic patients: a pilot study. J. Clin. Pharmacol. (1993) 13(4):264–267.
   Google Scholar
• VINCENT A, RISINGER R, SCHMIDT M, BARUCH P, LEMELINS, POTTER WZ: Idazoxan effects on attention in normal volunteers. American Psychiatric Association. Philadelphia (1994). Abstract.
   Google Scholar
• GLUE P, WILSON S, LAWSON CH, CAMPLING GM, FRANK-LIN M, COWEN PHJ, NUTT DJ: Acute and chronic ida-zoxan in normal volunteers: biochemical, physiological and psychological effects. J. Psychophar-macology (1991) 5(4):396–403.
   PubMedGoogle Scholar
• NICHOLSON AN, PASCOE PA: Presynaptic alpharad-renoceptor function in man: studies with clonidine and idazoxan. Neuropharmacology (1991) 30(4):367–372.
   PubMedGoogle Scholar
• OSMAN OT, RUDORFER MV, P01 lhR WZ: Chronic alphaz antagonism increases norepinephrine, blocks Gil re-lease and is antidepressant. Biological Psychiatty Meeting. San Francisco (1989). Abstract.
   Google Scholar
• SMITH AP, WILSON SJ, GLUE P, NUTT DJ: The effects of the alphaz-adrenoceptor antagonist idazoxan on mood memory and attention in normal volunteers. J. Psycho-pharmacol . (1992) 6:376–381.
   PubMedGoogle Scholar
• POLLAK P, LIMOUSIN P, GERVASON-TOURNIER CL, HOM-MEL M, PERRET JE: Ro-40-7562, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet (1993) 341:1605.
   Google Scholar
• SCHMIDT M, MATOCHIT J, RISINGER R, ZAMETKIN A, SCHOUTEN J, COHEN R, P011ER WZ: Effects of idazoxan on regional brain metabolism [Abstract]. Clinical Phar-macology & Therapeutics (1994)136.
   Google Scholar
• DONTENWILL M, BRICCA G, MOLINES A, BOUSQLTET P, BELCOURT A: Production and characterization of anti-clonidine antibodies not cross-reacting with catecho-lamittes. Eur. J. Pharmacol. (1988) 149:249–255.
   PubMed Web of Science ®Google Scholar
• DONTENWILL M, MOLINES A, VERDUN A, BRICCA G,
   Google Scholar
• •LAURENT S, BOUSQUET P: A circulating substance crossreacting with anti-imidazoline antibodies: detection in serum in relation with essential hypertension. J. Clin. Invest. (1993) 93:1068-1072. Pascal Bousquet, Laboratoire de Pharmacologie Cardiovasculaire et Rénale, Université Louis Pasteur, CNRS URA 589, Faculté de Médecine, 11 rue Humann, 67000 Strasbourg, France.
   Google Scholar